Top

Published in:

Open Access 01-03-2019 | Atopic Dermatitis | Review

Tolerability of Topical Treatments for Atopic Dermatitis

Authors: Zoe D. Draelos, Steven R. Feldman, Brian Berman, Melissa Olivadoti, Debra Sierka, Anna M. Tallman, Michael A. Zielinski, William C. Ports, Sheryl Baldwin

Published in: Dermatology and Therapy | Issue 1/2019

Abstract

Atopic dermatitis (AD) is a common inflammatory skin disease that is accompanied by increased sensitivity to itch-provoking and pain-provoking stimuli. Patients with AD experience skin pain before initiation of therapy and have also reported painful application site reactions in clinical trials of emollients and prescription topical therapies, including topical corticosteroids (TCSs), topical calcineurin inhibitors (TCIs), and a topical phosphodiesterase 4 (PDE4) inhibitor. To compare the sensory tolerability of prescription topical therapies for AD, a comprehensive literature search and analysis of published clinical trials was conducted. Sensory tolerability issues such as application site pain, burning, stinging, and pruritus were often among the most common adverse events or treatment-related adverse events in clinical trials for prescription topical therapies. Tolerability issues occurred at highest rates in trials of TCIs, followed by trials of the PDE4 inhibitor crisaborole and TCSs, although direct comparisons are not possible because of differences in study design. Tolerability issues in these clinical trials were generally mild to moderate and transient. This article also reviews published strategies for managing sensory tolerability issues in AD patients during treatment with topical therapies.

Funding: Pfizer Inc., New York, NY.

Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483–94. https://doi.org/10.1056/NEJMra074081.PubMedCrossRef

Bieber T. Atopic dermatitis. Ann Dermatol. 2010;22(2):125–37. https://doi.org/10.5021/ad.2010.22.2.125.PubMedPubMedCentralCrossRef

Vakharia PP, Chopra R, Sacotte R, et al. Burden of skin pain in atopic dermatitis. Ann Allergy Asthma Immunol. 2017;119(6):548-52.e3. https://doi.org/10.1016/j.anai.2017.09.076.CrossRef

O’Neill JL, Chan YH, Rapp SR, Yosipovitch G. Differences in itch characteristics between psoriasis and atopic dermatitis patients: results of a web-based questionnaire. Acta Derm Venereol. 2011;91(5):537–40. https://doi.org/10.2340/00015555-1126.PubMedCrossRef

Brenaut E, Garlantezec R, Talour K, Misery L. Itch characteristics in five dermatoses: non-atopic eczema, atopic dermatitis, urticaria, psoriasis and scabies. Acta Derm Venereol. 2013;93(5):573–4. https://doi.org/10.2340/00015555-1599.PubMedCrossRef

Yatagai T, Shimauchi T, Yamaguchi H, et al. Sensitive skin is highly frequent in extrinsic atopic dermatitis and correlates with disease severity markers but not necessarily with skin barrier impairment. J Dermatol Sci. 2018;89(1):33–9. https://doi.org/10.1016/j.jdermsci.2017.10.011.PubMedCrossRef

Andersen HH, Elberling J, Solvsten H, Yosipovitch G, Arendt-Nielsen L. Nonhistaminergic and mechanical itch sensitization in atopic dermatitis. Pain. 2017;158(9):1780–91. https://doi.org/10.1097/j.pain.0000000000000980.PubMedCrossRef

Misery L, Loser K, Stander S. Sensitive skin. J Eur Acad Dermatol Venereol. 2016;30(Suppl 1):2–8. https://doi.org/10.1111/jdv.13532.PubMedCrossRef

Tsutsumi M, Kitahata H, Fukuda M, et al. Numerical and comparative three-dimensional structural analysis of peripheral nerve fibres in epidermis of patients with atopic dermatitis. Br J Dermatol. 2016;174(1):191–4. https://doi.org/10.1111/bjd.13974.PubMedCrossRef

10.

Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–32. https://doi.org/10.1016/j.jaad.2014.03.023.PubMedPubMedCentralCrossRef

11.

Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol. 2013;131(2):295-9.e27. https://doi.org/10.1016/j.jaci.2012.12.672.CrossRef

12.

Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–82. https://doi.org/10.1111/jdv.14891.PubMedCrossRef

13.

Anacor Pharmaceuticals. EUCRISA (crisaborole) ointment, 2%, for topical use. Palo Alto: Anacor Pharmaceuticals; 2016.

14.

Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10-22.e2. https://doi.org/10.1016/j.anai.2017.10.039.PubMedCrossRef

15.

Akerstrom U, Reitamo S, Langeland T, et al. Comparison of moisturizing creams for the prevention of atopic dermatitis relapse: a randomized double-blind controlled multicentre clinical trial. Acta Derm Venereol. 2015;95(5):587–92. https://doi.org/10.2340/00015555-2051.PubMedCrossRef

16.

Angelova-Fischer I, Neufang G, Jung K, Fischer TW, Zillikens D. A randomized, investigator-blinded efficacy assessment study of stand-alone emollient use in mild to moderately severe atopic dermatitis flares. J Eur Acad Dermatol Venereol. 2014;28(Suppl 3):9–15. https://doi.org/10.1111/jdv.12479.PubMedCrossRef

17.

Gayraud F, Sayag M, Jourdan E. Efficacy and tolerance assessment of a new type of dermocosmetic in infants and children with moderate atopic dermatitis. J Cosmet Dermatol. 2015;14(2):107–12. https://doi.org/10.1111/jocd.12145.PubMedCrossRef

18.

Loden M, Andersson AC, Anderson C, et al. A double-blind study comparing the effect of glycerin and urea on dry, eczematous skin in atopic patients. Acta Derm Venereol. 2002;82(1):45–7.PubMedCrossRef

19.

Hebert AA, Cook-Bolden FE, Basu S, Calvarese B, Trancik RJ. Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis. J Drugs Dermatol. 2007;6(2):175–81.PubMed

20.

Friedlander SF, Hebert AA, Allen DB. Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol. 2002;46(3):387–93.PubMedCrossRef

21.

Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494-503.e6. https://doi.org/10.1016/j.jaad.2016.05.046.PubMedCrossRef

22.

Eichenfield LF, Call RS, Forsha DW, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2017;77(4):641-9.e5. https://doi.org/10.1016/j.jaad.2017.06.010.CrossRef

23.

Meurer M, Eichenfield LF, Ho V, Potter PC, Werfel T, Hultsch T. Addition of pimecrolimus cream 1% to a topical corticosteroid treatment regimen in paediatric patients with severe atopic dermatitis: a randomized, double-blind trial. J Dermatol Treat. 2010;21(3):157–66. https://doi.org/10.3109/09546630903410158.CrossRef

24.

Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002;46(4):495–504.PubMedCrossRef

25.

Kaufmann R, Bieber T, Helgesen AL, et al. Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. Allergy. 2006;61(3):375–81. https://doi.org/10.1111/j.1398-9995.2005.00977.x.PubMedCrossRef

26.

Murrell DF, Calvieri S, Ortonne JP, et al. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Br J Dermatol. 2007;157(5):954–9. https://doi.org/10.1111/j.1365-2133.2007.08192.x.PubMedCrossRef

27.

Hoeger PH, Lee KH, Jautova J, et al. The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial. Br J Dermatol. 2009;160(2):415–22. https://doi.org/10.1111/j.1365-2133.2008.08928.x.PubMedCrossRef

28.

Eichenfield LF, Lucky AW, Langley RG, et al. Use of pimecrolimus cream 1% (Elidel) in the treatment of atopic dermatitis in infants and children: the effects of ethnic origin and baseline disease severity on treatment outcome. Int J Dermatol. 2005;44(1):70–5. https://doi.org/10.1111/j.1365-4632.2004.02234.x.PubMedCrossRef

29.

Zuberbier T, Heinzerling L, Bieber T, Schauer U, Klebs S, Brautigam M. Steroid-sparing effect of pimecrolimus cream 1% in children with severe atopic dermatitis. Dermatology. 2007;215(4):325–30. https://doi.org/10.1159/000107627.PubMedCrossRef

30.

Zuberbier T, Brautigam M. Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease. J Eur Acad Dermatol Venereol. 2008;22(6):718–21. https://doi.org/10.1111/j.1468-3083.2008.02586.x.PubMedCrossRef

31.

Sigurgeirsson B, Ho V, Ferrandiz C, Andriano K, Grinienko A, Jimenez P. Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis. J Eur Acad Dermatol Venereol. 2008;22(11):1290–301. https://doi.org/10.1111/j.1468-3083.2008.02785.x.PubMedCrossRef

32.

Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110(1 Pt 1):e2.PubMedCrossRef

33.

Meurer M, Fartasch M, Albrecht G, et al. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology (Basel, Switzerland). 2004;208(4):365–72. https://doi.org/10.1159/000078462.PubMedCrossRef

34.

Meurer M, Folster-Holst R, Wozel G, Weidinger G, Junger M, Brautigam M. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology. 2002;205(3):271–7. https://doi.org/10.1159/000065863.PubMedCrossRef

35.

Lubbe J, Friedlander SF, Cribier B, et al. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am J Clin Dermatol. 2006;7(2):121–31. https://doi.org/10.2165/00128071-200607020-00005.PubMedCrossRef

36.

Simon D, Lubbe J, Wuthrich B, et al. Benefits from the use of a pimecrolimus-based treatment in the management of atopic dermatitis in clinical practice. Analysis of a Swiss cohort. Dermatology. 2006;213(4):313–8. https://doi.org/10.1159/000096195.PubMedCrossRef

37.

Ring J, Abraham A, de Cuyper C, Kim K, Langeland T, Parra V, et al. Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study. J Eur Acad Dermatol Venereol JEADV. 2008;22(2):195–203. https://doi.org/10.1111/j.1468-3083.2007.02368.x.PubMedCrossRef

38.

De Backer M, Morren MA, Boonen H, et al. Belgian observational drug utilization study of pimecrolimus cream 1% in routine daily practice in atopic dermatitis. Dermatology (Basel, Switzerland). 2008;217(2):156–63. https://doi.org/10.1159/000136654.PubMedCrossRef

39.

Langley RG, Eichenfield LF, Lucky AW, Boguniewicz M, Barbier N, Cherill R. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis. Pediatr Dermatol. 2008;25(3):301–7. https://doi.org/10.1111/j.1525-1470.2008.00671.x.PubMedCrossRef

40.

Ruer-Mulard M, Aberer W, Gunstone A, et al. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis. Pediatr Dermatol. 2009;26(5):551–8. https://doi.org/10.1111/j.1525-1470.2009.00981.x.PubMedCrossRef

41.

Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr. 2003;142(2):155–62. https://doi.org/10.1067/mpd.2003.65.PubMedCrossRef

42.

Kang S, Paller A, Soter N, Satoi Y, Rico MJ, Hanifin JM. Safe treatment of head/neck AD with tacrolimus ointment. J Dermatol Treat. 2003;14(2):86–94.CrossRef

43.

Lan CC, Huang CC, Chen YT, Wang LF, Lin CT, Chen GS. Tacrolimus ointment for the treatment of atopic dermatitis: report of first clinical experience in Taiwan. Kaohsiung J Med Sci. 2003;19(6):296–304. https://doi.org/10.1016/S1607-551X(09)70476-0.PubMedCrossRef

44.

Schachner LA, Lamerson C, Sheehan MP, et al. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study. Pediatrics. 2005;116(3):e334–42. https://doi.org/10.1542/peds.2004-2638.PubMedCrossRef

45.

Singalavanija S, Noppakun N, Limpongsanuruk W, et al. Efficacy and safety of tacrolimus ointment in pediatric patients with moderate to severe atopic dermatitis. J Med Assoc Thai. 2006;89(11):1915–22.PubMed

46.

Won CH, Seo PG, Park YM, et al. A multicenter trial of the efficacy and safety of 0.03% tacrolimus ointment for atopic dermatitis in Korea. J Dermatol Treat. 2004;15(1):30–4. https://doi.org/10.1080/09541440042000269.CrossRef

47.

Tan J, Langley R. Safety and efficacy of tacrolimus ointment 0.1% (protopic) in atopic dermatitis: a Canadian open-label multicenter study. J Cutan Med Surg. 2004;8(4):213–9. https://doi.org/10.1177/120347540400800402.PubMedCrossRef

48.

Reitamo S, Wollenberg A, Schopf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol. 2000;136(8):999–1006.PubMedCrossRef

49.

Reitamo S, Ortonne JP, Sand C, et al. Long-term treatment with 0.1% tacrolimus ointment in adults with atopic dermatitis: results of a two-year, multicentre, non-comparative study. Acta Derm Venereol. 2007;87(5):406–12. https://doi.org/10.2340/00015555-0282.PubMedCrossRef

50.

Remitz A, Harper J, Rustin M, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. Acta Derm Venereol. 2007;87(1):54–61. https://doi.org/10.2340/00015555-0167.PubMedCrossRef

51.

Reitamo S, Rustin M, Harper J, et al. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol. 2008;159(4):942–51. https://doi.org/10.1111/j.1365-2133.2008.08747.x.PubMedCrossRef

52.

Wollenberg A, Reitamo S, Atzori F, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy. 2008;63(6):742–50. https://doi.org/10.1111/j.1398-9995.2008.01683.x.PubMedCrossRef

53.

Thaci D, Reitamo S, Gonzalez Ensenat MA, et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol. 2008;159(6):1348–56. https://doi.org/10.1111/j.1365-2133.2008.08813.x.PubMedCrossRef

54.

Reitamo S, Allsopp R. Treatment with twice-weekly tacrolimus ointment in patients with moderate to severe atopic dermatitis: results from two randomized, multicentre, comparative studies. J Dermatol Treat. 2010;21(1):34–44. https://doi.org/10.3109/09546630903401488.CrossRef

55.

Breneman D, Fleischer AB Jr, Abramovits W, et al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol. 2008;58(6):990–9. https://doi.org/10.1016/j.jaad.2008.02.008.PubMedCrossRef

56.

Paller AS, Eichenfield LF, Kirsner RS, Shull T, Jaracz E, Simpson EL. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use. Pediatrics. 2008;122(6):e1210–8. https://doi.org/10.1542/peds.2008-1343.PubMedCrossRef

57.

Kempers S, Boguniewicz M, Carter E, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol. 2004;51(4):515–25. https://doi.org/10.1016/j.jaad.2004.01.051.PubMedCrossRef

58.

Paller AS, Lebwohl M, Fleischer AB Jr, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol. 2005;52(5):810–22. https://doi.org/10.1016/j.jaad.2004.12.038.PubMedCrossRef

59.

Fleischer AB Jr, Abramovits W, Breneman D, Jaracz E. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. J Dermatol Treat. 2007;18(3):151–7. https://doi.org/10.1080/09546630701287332.CrossRef

60.

Abramovits W, Fleischer AB Jr, Jaracz E, Breneman D. Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream. J Drugs Dermatol. 2008;7(12):1153–8.PubMed

61.

Kirsner RS, Heffernan MP, Antaya R. Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids. Acta Derm Venereol. 2010;90(1):58–64. https://doi.org/10.2340/00015555-0748.PubMedCrossRef

62.

Meingassner JG, Aschauer H, Stuetz A, Billich A. Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid-pretreated skin. Exp Dermatol. 2005;14(10):752–7. https://doi.org/10.1111/j.1600-0625.2005.00354.x.PubMedCrossRef

63.

Kirkup ME, Birchall NM, Weinberg EG, Helm K, Kennedy CT. Acute and maintenance treatment of atopic dermatitis in children—two comparative studies with fluticasone propionate (0.05%) cream. J Dermatol Treat. 2003;14(3):141–8.CrossRef

64.

Eichenfield LF, Miller BH. Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from 3 months of age. J Am Acad Dermatol. 2006;54(4):715–7. https://doi.org/10.1016/j.jaad.2005.10.063.PubMedCrossRef

65.

Abramovits W, Oquendo M. Hydrocortisone butyrate 0.1% lipocream in pediatric patients with atopic dermatitis. Skinmed. 2010;8(2):72–9.PubMed

66.

Matheson R, Kempers S, Breneman D, et al. Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjects. J Drugs Dermatol. 2008;7(3):266–71.PubMed

67.

Hebert AA. Desonide foam 0.05%: safety in children as young as 3 months. J Am Acad Dermatol. 2008;59(2):334–40. https://doi.org/10.1016/j.jaad.2008.04.019.PubMedCrossRef

68.

Faergemann J, Christensen O, Sjovall P, et al. An open study of efficacy and safety of long-term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2000;14(5):393–6.PubMedCrossRef

69.

Peserico A, Stadtler G, Sebastian M, Fernandez RS, Vick K, Bieber T. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol. 2008;158(4):801–7. https://doi.org/10.1111/j.1365-2133.2008.08436.x.PubMedCrossRef

70.

Cato A, Swinehart JM, Griffin EI, Sutton L, Kaplan AS. Azone enhances clinical effectiveness of an optimized formulation of triamcinolone acetonide in atopic dermatitis. Int J Dermatol. 2001;40(3):232–6.PubMedCrossRef

71.

Paller AS, Nimmagadda S, Schachner L, et al. Fluocinolone acetonide 0.01% in peanut oil: therapy for childhood atopic dermatitis, even in patients who are peanut sensitive. J Am Acad Dermatol. 2003;48(4):569–77. https://doi.org/10.1067/mjd.2003.174.PubMedCrossRef

72.

Luger TA, Lahfa M, Folster-Holst R, et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatol Treat. 2004;15(3):169–78. https://doi.org/10.1080/09546630410033781.CrossRef

73.

Reitamo S, Van Leent EJ, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol. 2002;109(3):539–46.PubMedCrossRef

74.

Reitamo S, Harper J, Bos JD, et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol. 2004;150(3):554–62. https://doi.org/10.1046/j.1365-2133.2004.05782.x.PubMedCrossRef

75.

Rahman MF, Nandi AK, Kabir S, Kamal M, Basher MS, Banu LA. Topical tacrolimus versus hydrocortisone on atopic dermatitis in paediatric patients: a randomized controlled trial. Mymensingh Med J. 2015;24(3):457–63.PubMed

76.

Reitamo S, Ortonne JP, Sand C, et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol. 2005;152(6):1282–9. https://doi.org/10.1111/j.1365-2133.2005.06592.x.PubMedCrossRef

77.

Bieber T, Vick K, Folster-Holst R, et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy. 2007;62(2):184–9. https://doi.org/10.1111/j.1398-9995.2006.01269.x.PubMedCrossRef

78.

Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol. 2002;109(3):547–55.PubMedCrossRef

79.

Doss N, Kamoun MR, Dubertret L, et al. Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment. Pediatr Allergy Immunol. 2010;21(2 Pt 1):321–9. https://doi.org/10.1111/j.1399-3038.2009.00895.x.PubMedCrossRef

80.

Doss N, Reitamo S, Dubertret L, et al. Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial. Br J Dermatol. 2009;161(2):427–34. https://doi.org/10.1111/j.1365-2133.2009.09143.x.PubMedCrossRef

81.

Siegfried EC, Jaworski JC, Hebert AA. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am J Clin Dermatol. 2013;14(3):163–78. https://doi.org/10.1007/s40257-013-0020-1.PubMedPubMedCentralCrossRef

82.

Weber TM, Herndon JH Jr, Ewer M, et al. Efficacy and tolerability of steroid-free, over-the-counter treatment formulations in infants and children with atopic dermatitis. J Dermatol Nurses Assoc. 2015;7(1):17–24. https://doi.org/10.1097/JDN.0000000000000101.PubMedPubMedCentralCrossRef

83.

van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen A, Arents BWM. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017;2:CD012119. https://doi.org/10.1002/14651858.cd012119.pub2.PubMedCrossRef

84.

Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000;9(3):165–9.PubMedCrossRef

85.

Mandelin J, Remitz A, Reitamo S. Effect of oral acetylsalicylic acid on burning caused by tacrolimus ointment in patients with atopic dermatitis. Arch Dermatol. 2010;146(10):1178–80. https://doi.org/10.1001/archdermatol.2010.275.PubMedCrossRef

86.

Greffrath W, Kirschstein T, Nawrath H, Treede RD. Acetylsalicylic acid reduces heat responses in rat nociceptive primary sensory neurons—evidence for a new mechanism of action. Neurosci Lett. 2002;320(1–2):61–4.PubMedCrossRef

87.

Pereira U, Boulais N, Lebonvallet N, Pennec JP, Dorange G, Misery L. Mechanisms of the sensory effects of tacrolimus on the skin. Br J Dermatol. 2010;163(1):70–7. https://doi.org/10.1111/j.1365-2133.2010.09757.x.PubMedCrossRef

88.

Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl. 1989;144:13–4.

Title: Tolerability of Topical Treatments for Atopic Dermatitis
Authors: Zoe D. Draelos
Steven R. Feldman
Brian Berman
Melissa Olivadoti
Debra Sierka
Anna M. Tallman
Michael A. Zielinski
William C. Ports
Sheryl Baldwin
Publication date: 01-03-2019
Publisher: Springer Healthcare
Keywords: Atopic Dermatitis
Pruritus
Fluticasone
Tacrolimus
Calcineurin Inhibitors
Published in: Dermatology and Therapy / Issue 1/2019
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI: https://doi.org/10.1007/s13555-019-0280-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

Evaluation of Antibiotic Treatment on the Duration of Hospitalization of Patients with Erysipelas and Bacterial Cellulitis

A Case Report of Scrotal Rejuvenation: Laser Treatment of Angiokeratomas of the Scrotum

Propionibacterium (Cutibacterium) acnes Bacteriophage Therapy in Acne: Current Evidence and Future Perspectives

A Summary of 2018 and What Lies Ahead for Dermatology and Therapy in 2019

New Vision in Photoprotection and Photorepair

Self-Assessments of Standardized Scalp Massages for Androgenic Alopecia: Survey Results

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage